The estimated Net Worth of Tom Gwydir is at least $20.8 Tisíc dollars as of 18 August 2021. Tom Gwydir owns over 5,000 units of Nephros Inc stock worth over $20,793 and over the last 6 years Tom sold NEPH stock worth over $0.
Tom has made over 1 trades of the Nephros Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Tom bought 5,000 units of NEPH stock worth $38,200 on 18 August 2021.
The largest trade Tom's ever made was buying 5,000 units of Nephros Inc stock on 18 August 2021 worth over $38,200. On average, Tom trades about 833 units every 0 days since 2019. As of 18 August 2021 Tom still owns at least 11,031 units of Nephros Inc stock.
You can see the complete history of Tom Gwydir stock trades at the bottom of the page.
Tom's mailing address filed with the SEC is C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE, NJ, 07079.
Over the last 6 years, insiders at Nephros Inc have traded over $0 worth of Nephros Inc stock and bought 188,822 units worth $443,998 . The most active insiders traders include Capital Lp Wexford Gp Llcda..., Robert R. Jr. Banks a Andrew Astor. On average, Nephros Inc executives and independent directors trade stock every 70 days with the average trade being worth of $15,834. The most recent stock trade was executed by Arthur H Amron on 28 May 2024, trading 5,000 units of NEPH stock currently worth $11,200.
nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil
Nephros Inc executives and other stock owners filed with the SEC include: